<DOC>
	<DOC>NCT01711281</DOC>
	<brief_summary>Heart Failure (HF) is one of the most frequent diagnoses upon hospitalization and is a major cause of death. Cardiac resynchronization therapy (CRT) using an implantable device for synchronous bi-ventricular stimulation leads to improvement of hemodynamic parameters, physical capacity and quality of life. A continuous measurement of the left-ventricular volume would provide information about heart performance and could be used for both heart failure monitoring and optimization of CRT-therapy.</brief_summary>
	<brief_title>Monitoring of Hemodynamics in Heart Failure Patients by Intracardiac Impedance Measurement</brief_title>
	<detailed_description />
	<mesh_term>Heart Failure</mesh_term>
	<criteria>De novo CRTpatients Planned implantation with a Lumax 740 HFT device, a bipolar LVlead and a true bipolar RVlead NYHA class II or III QRS ≥ 150 ms LVEF between 15% and 35% LVEDD ≥ 55 mm Evaluable echo measurements Persistent or permanent atrial fibrillation Heart surgery within the previous 3 months or planned for the time of study participation; postheart transplantation or listed for heart transplantation Nonambulatory patients Chronic renal dialysis Life expectancy less than 1 year due to a noncardiac disease Age &lt; 18 years and/or limited contractual capability Addiction to alcohol, medical drugs or illegal drugs Pregnant or breastfeeding women Participation in another clinical trial</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2015</verification_date>
	<keyword>Heart Failure</keyword>
	<keyword>Implantable Cardioverter-Defibrillator</keyword>
	<keyword>Intracardiac Impedance Measurement</keyword>
	<keyword>Cardiac Resynchronization Therapy</keyword>
	<keyword>Home Monitoring</keyword>
	<keyword>Reverse Remodeling</keyword>
</DOC>